Welcome to Drug Discovery Online Live – An interactive forum exploring the most critical innovations and strategies shaping the future of drug development. Throughout the year, our editors engage leading scientists, technologists, and industry executives in conversations about how companies are tackling challenges across discovery, preclinical research, and translational science. These discussions often address topics such as emerging modalities, AI-driven approaches, regulatory considerations, and technology trends. Each Drug Discovery Online Live session includes opportunities for audience Q&A. Videos of the full session and featured segments will be archived for on-demand access by registered site users.
ORGANS-ON-CHIPS: TECH PROGRESS & REGULATORY TAILWINDS
Organs-On-Chips: Tech Progress And Regulatory Tailwinds
The panel discussed the progress being made in microphysiological systems (MPS) and the future of organ-on-chip research models.
WHY OPEN-SOURCE MODELS MATTER FOR COMPUTATIONAL DRUG DISCOVERY
Why Open-Source Models Matter for Computational Drug Discovery
Panel explored open source AI tools in drug discovery, from structure prediction to antibiotics, with leaders from Boltz, OpenFold, McMaster University, and Drug Discovery Online.
THE NAMS REVOLUTION: SMARTER, SAFER, MORE ETHICAL DRUG TESTING
The NAMs Revolution: Smarter, Safer, More Ethical Drug Testing
The virtual panel, moderated by Ray Dogum, explored the rise of New Approach Methodologies (NAMs) in drug development. Speakers included Dr. Samantha Atkins (organ-on-chip expert), Dr. Shashi Ramaiah (former Pfizer executive and founder of SPECCRO Inc.), and Dr. Zaher Nah...
DRUG DISCOVERY ONLINE LIVE - 2026 EVENT SCHEDULE
Mar. 26: Why Open-Source Models Matter for Computational Drug Discovery (On Demand)
May 5: Organs-on-Chips: Tech Progress & Regulatory Tailwinds
Jun. 30: Drugging the Undruggable with PROTACs
Sept. 9: Inside the Organoid Services Ecosystem for Drug Discovery
Oct. 27: Integrating Multiomics and Computation in Modern Drug Discovery
Nov. 19: Unlocking the Untapped Value of Radiopharmaceuticals
MEET OUR HOST
Ray Dogum is the Chief Editor of Drug Discovery Online, where he curates and leads editorial content focused on the earliest phases of drug development—from target identification and hit discovery to preclinical validation. With a background in chemical engineering and master's degrees in business and information systems from Boston University’s Questrom School of Business, Ray brings a cross-disciplinary perspective to the future of therapeutic innovation.
Connect with Ray Dogum on LinkedIn: https://www.linkedin.com/in/raydogum/